AT2 Receptor Activation Prevents Sodium Retention and Reduces Blood Pressure in Angiotensin II-Dependent Hypertension

Circulation Research

Volumn 119, Issue 4, 2016, Pages 532-543

  Kemp, Brandon A ^a   Howell, Nancy L ^a   Keller, Susanna R ^a   Gildea, John J ^b   Padia, Shetal H ^a   Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

blood pressure; hypertension; kidney; natriuresis; sodium channels

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; AMILORIDE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN AT2 RECEPTOR AGONIST; ANGIOTENSIN II; CHLOROTHIAZIDE; CREATININE; HORMONE RECEPTOR STIMULATING AGENT; POTASSIUM; RENIN; SODIUM; SODIUM PROTON EXCHANGE PROTEIN 3; UNCLASSIFIED DRUG; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG POTENTIATION; EXPERIMENTAL HYPERTENSION; FEMALE; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RAT; SODIUM BALANCE; SODIUM RETENTION; SODIUM URINE LEVEL; AGONISTS; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; URINE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; FEMALE; HYPERTENSION; NATRIURESIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; SODIUM; SULFONAMIDES; THIOPHENES;

EID: 84978069608     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308384     Document Type: Article

References (43)

1. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271. doi: 10.1210/er.2003-0001.
2. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960-975. doi: 10.1161/CIRCRESAHA. 116.303587.
3. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316. doi: 10.1016/j.pharmthera.2008.08.009.
4. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005;45:840-844. doi: 10.1161/01.HYP.0000159192.93968.8f.
5. Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013;465:99-110. doi: 10.1007/s00424-012-1146-3.
6. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584-594.
7. Guyton AC. The surprising kidney-fluid mechanism for pressure control-its infinite gain! Hypertension. 1990;16:725-730.
8. Li H, Weatherford ET, Davis DR, Keen HL, Grobe JL, Daugherty A, Cassis LA, Allen AM, Sigmund CD. Renal proximal tubule angiotensin AT1A receptors regulate blood pressure. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1067-R1077. doi: 10.1152/ ajpregu.00124.2011.
9. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA. 2006;103:17985-17990. doi: 10.1073/ pnas.0605545103.
10. Gurley SB, Riquier-Brison AD, Schnermann J, Sparks MA, Allen AM, Haase VH, Snouwaert JN, Le TH, McDonough AA, Koller BH, Coffman TM. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 2011;13:469-475. doi: 10.1016/j. cmet.2011.03.001.
11. Li XC, Zhuo JL. Proximal tubule-dominant transfer of AT(1a) receptors induces blood pressure responses to intracellular angiotensin II in AT(1a) receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2013;304:R588-R598. doi: 10.1152/ajpregu.00338.2012.
12. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30:1238-1246.
13. Miyata N, Park F, Li XF, Cowley AW Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol. 1999;277:F437-F446.
14. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. doi: 10.1021/jm049715t.
15. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011;121:297-303. doi: 10.1042/ CS20110036.
16. Kemp BA, Howell NL, Gildea JJ, Keller SR, Padia SH, Carey RM. AT2 receptor activation induces natriuresis and lowers blood pressure. Circ Res. 2014;115:388-399. doi: 10.1161/CIRCRESAHA. 115.304110.
17. Hilliard LM, Mirabito KM, Denton KM. Unmasking the potential of the angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: what we know and what we still need to find out. Clin Exp Pharmacol Physiol. 2013;40:542-550. doi: 10.1111/1440-1681.12067.
18. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291-299. doi: 10.1161/ HYPERTENSIONAHA.111.180158.
19. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437-445. doi: 10.1161/ HYPERTENSIONAHA.111.184788.
20. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709-716. doi: 10.1111/j.1476-5381.2009.00575.x.
21. Padia SH, Howell NL, Kemp BA, Fournie-Zaluski MC, Roques BP, Carey RM. Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats. Hypertension. 2010;55:474-480. doi: 10.1161/ HYPERTENSIONAHA.109.144956.
22. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, Carey RM. Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension. 2009;53:338-343. doi: 10.1161/ HYPERTENSIONAHA.108.124198.
23. Hein L, Meinel L, Pratt RE, Dzau VJ, Kobilka BK. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol. 1997;11:1266-1277. doi: 10.1210/mend.11.9.9975.
24. Gwathmey TM, Shaltout HA, Pendergrass KD, Pirro NT, Figueroa JP, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol. 2009;296:F1484-F1493. doi: 10.1152/ ajprenal.90766.2008.
25. Presig PA, Rector FG Jr. Role of Na+-K+ antiport in rat proximal tubule NaCl absorption. Am J Physiol Renal Physiol. 1988;255:F461-F465.
26. Aronson PS. Role of ion exchangers in mediating NaCl transport in the proximal tubule. Kidney Int. 1996;49:1665-1670.
27. Wang T. Flow-activated transport events along the nephron. Curr Opin Nephrol Hypertens. 2006;15:530-536. doi: 10.1097/01.mnh.0000242180. 46362.c4.
28. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, Riddle TM, Duffy JJ, Doetschman T, Wang T, Giebisch G, Aronson PS, Lorenz JN, Shull GE. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet. 1998;19:282-285. doi: 10.1038/969.
29. Ledoussal C, Lorenz JN, Nieman ML, Soleimani M, Schultheis PJ, Shull GE. Renal salt wasting in mice lacking NHE3 Na+/H+ exchanger but not in mice lacking NHE2. Am J Physiol Renal Physiol. 2001;281:F718-F727.
30. Girardi AC, Di Sole F. Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunction. Am J Physiol Cell Physiol. 2012;302:C1569-C1587. doi: 10.1152/ajpcell.00017.2012.
31. Biemesderfer D, Pizzonia J, Abu-Alfa A, Exner M, Reilly R, Igarashi P, Aronson PS. NHE3: a Na+/H+ exchanger isoform of renal brush border. Am J Physiol. 1993;265:F736-F742.
32. Riquier AD, Lee DH, McDonough AA. Renal NHE3 and NaPi2 partition into distinct membrane domains. Am J Physiol Cell Physiol. 2009;296:C900-C910. doi: 10.1152/ajpcell.00526.2008.
33. Donowitz M, Li X. Regulatory binding partners and complexes of NHE3. Physiol Rev. 2007;87:825-872. doi: 10.1152/physrev.00030.2006.
34. Moe OW, Amemiya M, Yamaji Y. Activation of protein kinase A acutely inhibits and phosphorylates Na/H exchanger NHE-3. J Clin Invest. 1995;96:2187-2194. doi: 10.1172/JCI118273.
35. Zhao H, Wiederkehr MR, Fan L, Collazo RL, Crowder LA, Moe OW. Acute inhibition of Na/H exchanger NHE-3 by cAMP. Role of protein kinase a and NHE-3 phosphoserines 552 and 605. J Biol Chem. 1999;274:3978-3987.
36. Kocinsky HS, Girardi AC, Biemesderfer D, Nguyen T, Mentone S, Orlowski J, Aronson PS. Use of phospho-specific antibodies to determine the phosphorylation of endogenous Na+/H+ exchanger NHE3 at PKA consensus sites. Am J Physiol Renal Physiol. 2005;289:F249-F258. doi: 10.1152/ajprenal.00082.2004.
37. Kurashima K, Yu FH, Cabado AG, Szabó EZ, Grinstein S, Orlowski J. Identification of sites required for down-regulation of Na+/H+ exchanger NHE3 activity by cAMP-dependent protein kinase. phosphorylation-dependent and-independent mechanisms. J Biol Chem. 1997;272:28672-28679.
38. Belusa R, Wang ZM, Matsubara T, Sahlgren B, Dulubova I, Nairn AC, Ruoslahti E, Greengard P, Aperia A. Mutation of the protein kinase C phosphorylation site on rat alpha1 Na+,K+-ATPase alters regulation of intracellular Na+ and pH and influences cell shape and adhesiveness. J Biol Chem. 1997;272:20179-20184.
39. Therien AG, Blostein R. Mechanisms of sodium pump regulation. Am J Physiol Cell Physiol. 2000;279:C541-C566.
40. Kava L, Rossi NF, Mattingly R, Yingst DR. Increased expression of Na,KATPase and a selective increase in phosphorylation at Ser-11 in the cortex of the 2-kidney, 1-clip hypertensive rat. Am J Hypertens. 2012;25:487-491. doi: 10.1038/ajh.2011.247.
41. Nascimento NR, Kemp BA, Howell NL, Gildea JJ, Santos CF, Harris TE, Carey RM. Role of SRC family kinase in extracellular renal cyclic guanosine 3',5'-monophosphate-and pressure-induced natriuresis. Hypertension. 2011;58:107-113. doi: 10.1161/ HYPERTENSIONAHA.110.168708.
42. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, Stas S, Kumar P, Sha Q, Ferrario CM, Sowers JR. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab. 2005;288:E353-E359. doi: 10.1152/ajpendo.00402.2004.
43. Wenceslau CF, Rossoni LV. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/ cSRC pathway. J Hypertens. 2014;32:542-554. doi: 10.1097/HJH.0000000000000059.